Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Anlotinib in Liver Dysfunction
NCT05559242Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anlotinib in solid tumor, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak Concentration, Area Under Curve (0-t) and 1 more. Status: unknown.
02
Drugs
anlotinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05559242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559242.